Oct 11, 2017 by Brian Orelli, PhDWhy MannKind Corporation Dropped a Day After It Ran UpThe biotech is raising cash after seeing its shares triple over the last month.
Oct 10, 2017 by Brian Orelli, PhDThis Company Gained 76% in Its IPO -- and It Isn't Even a Tech CompanyInvestors were excited about the initial public offering of this obesity-drug biotech.
Oct 9, 2017 by Brian Orelli, PhDWhy DaVita Inc. Sank Lower TodayAn analyst downgrade sent shares of the dialysis company heading south.
Oct 9, 2017 by Brian Orelli, PhDWhy K2M Group Holdings Inc. Sank TodayDisappointing preliminary third-quarter revenue from the medical-device company has shares trading lower.
Oct 5, 2017 by Brian Orelli, PhDWhy ImmunoGen, Inc. Dropped TodayA secondary offering dilutes shareholders.
Oct 3, 2017 by Brian Orelli, PhDWhy PTC Therapeutics, Inc. Dropped TodayInvestors are unimpressed with data -- so far -- for the biotech's spinal muscular atrophy drug RG7916.
Oct 2, 2017 by Brian Orelli, PhDWhy AcelRx Pharmaceuticals Inc Jumped Higher TodayInvestors are buying ahead of an upcoming binary event.
Oct 2, 2017 by Brian Orelli, PhDCantel Medical Corp. Closes Out the Year With a Solid Mix of GrowthThe medical supply company is well on its way to meeting its five-year goal of doubling revenue and profit.
Sep 28, 2017 by Brian Orelli, PhDShould You Invest in This Marijuana ETF?ETFs are great for instant diversification -- but maybe not in this case.
Sep 28, 2017 by Brian Orelli, PhDBetter Buy: Bellicum Pharmaceuticals, Inc. vs. bluebird bioThere's more than meets the eye to both of these CAR-T biotechs.
Sep 28, 2017 by Brian Orelli, PhDWhy Advanced Accelerator Application SA Stock Jumped Higher TodayAn acquisition rumor has the radiopharmaceutical company's shares on the rise.
Sep 25, 2017 by Brian Orelli, PhDWhy Celldex Therapeutics, Inc. Jumped Higher TodayIt's a biotech thing.
Sep 22, 2017 by Brian Orelli, PhDWhy Exelixis, Inc. Slumped TodayConcerns over valuation have investors worried.
Sep 22, 2017 by Brian Orelli, PhDWhy Is Cash-Rich Gilead Sciences, Inc. Borrowing $3 Billion?The biotech has $36.6 billion on the books, but the money might not be sitting in the right account.
Sep 20, 2017 by Brian Orelli, PhDWhy Alnylam Pharmaceuticals, Inc. Skyrocketed and Ionis Pharmaceuticals Inc Sank TodayOne biotech's phase 3 success means competition for the other.
Sep 15, 2017 by Brian Orelli, PhDWhy Abeona Therapeutics Inc Stock Jumped Higher TodayAn analyst started coverage at a buy, but there's more that long-term investors should be focused on.
Sep 14, 2017 by Brian Orelli, PhDExelixis, Inc. and Bristol-Myers Squibb Co. Gear Up for Round 2 of the Kidney Cancer Drug Battle RoyaleIronically, round three could have the companies fighting on the same side.
Sep 13, 2017 by Brian Orelli, PhDGilead Sciences, Inc.'s Best Investment of 2017 (Hint: It Wasn't Kite Pharmaceuticals)Kite is a good buy, but this investment will have a bigger short-term effect.
Sep 12, 2017 by Brian Orelli, PhDWhy Shares of ImmunoGen, Inc. Sank TodayA little dilution has investors worried.
Sep 7, 2017 by Brian Orelli, PhDAre You Buying Gilead Sciences, Inc. for the Wrong Reason?The acquisition of Kite Pharma is a good move, but don't get caught up in the hype of Novartis' approval for Kymriah, which uses the same technology as Kite.
